Clinical trials: Insulin, completed
T2DM (Type 2 Diabetes Mellitus)
A Study to Evaluate the Efficacy and Safety of ORMD-0801 (Oral Insulin) in Patients With Type 2 Diabetes Mellitus
This is a four-way (Participant, Care Provider, Investigator, Outcomes Assessor) masked (blinded) study designed to explore the efficacy of ORMD-0801 when given in different regimens across a dose range for up to 12 weeks in…
- Trial name
- NCT03467932
- Testing
- Cohort A: ORMD-0801, Cohort B: ORMD-0801
- Where
- United States
- Volunteers
- 373 people
- Sponsor
- Oramed, Ltd.
Diabetes Mellitus, Type 1
A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works
This study is designed to investigate the movement of insulin NNC0363-0845 throughout the body and how it works for the treatment of type 1 diabetes mellitus.
- Trial name
- NCT05134987
- Testing
- NNC0363-0845, Insulin detemir
- Where
- Austria
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Phase 2 Study of LY3209590 in Participants With Type 2 Diabetes Mellitus
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 2 diabetes.
- Trial name
- NCT04450394
- Testing
- LY3209590, Insulin Degludec
- Where
- 64 sites in United States, Argentina and 3 more
- Volunteers
- 278 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1
Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.
The purpose of the proposed study is to compare insulin Degludec [TRESIBA® (insulin degludec injection)] with insulin Glargine U100 [Lantus® (insulin glargine injection)] to determine the basal insulin of choice for adults with…
- Trial name
- SafrTravlT1D (NCT03668808)
- Testing
- Insulin Degludec, Insulin Glargine, TRESIBA® FLEXTOUCH®
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Sansum Diabetes Research Institute
Type 2 Diabetes
Comparing the Effects of Insulin Glargine on Blood Glucose Between Needle-free Jet Injection and Insulin Pen
To comparing the blood sugar improvement and patient sensibility of insulin glargine injected with needle-free jet injector and conventional insulin pen
- Trial name
- NCT04074603
- Testing
- The needle-free jet injector, Conventional insulin pen
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Jian-hua Ma
Type 1 Diabetes Mellitus
A Study of LY3209590 in Participants With Type 1 Diabetes
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.
- Trial name
- NCT04450407
- Testing
- LY3209590, Insulin Degludec
- Where
- 54 sites in United States, Austria and 3 more
- Volunteers
- 266 people
- Sponsor
- Eli Lilly and Company
Intraoperative Complications
Intravenous Bolus-infusion Versus Sliding Scale of Insulin for Intra-operative Glycemic Control
Pre-operative blood glucose (BG) concentrations in type 2 diabetic patients undergoing elective non-cardiac surgery; have an increased incidence of in-hospital morbidity for cardiopulmonary and infectious complications.
- Trial name
- NCT05136157
- Testing
- Rapid-Acting Insulin
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Diabetes Mellitus
Comparison of Glycemic Control With Smartphone Application
The study is aimed to determine if a smartphone application based weekly glucose monitoring by a care provider is superior to the routine home glucose monitoring by patients in poorly controlled type 2 diabetes mellitus who are…
- Trial name
- NCT05592860
- Testing
- Mobile application, Daily Diary
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
A Continuous Glucose Monitor Based Insulin Bolus Calculator
This study examines the safety of an app-based insulin bolus calculator that utilizes glucose values from a continuous glucose monitor
- Trial name
- CGM-IBC (NCT05229445)
- Testing
- continuous glucose monitor based insulin bolus calculator
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Welldoc
Type 2 Diabetes
A Clinical Study Comparing the Pharmacokinetics and Pharmacodynamic Characteristics of Insulin Degludec Injection (RD15003) and Insulin Degludec Injection (Tresiba®) in Healthy Subjects
To evaluate the single-dose subcutaneous injection of insulin degludec injection (Tresiba®) listed by Novo Nordisk in China as a reference drug, the insulin degludec injection provided by Dongguan Dongyang Sunshine…
- Trial name
- NCT05576298
- Testing
- Insulin degludec injection, RD15003, Insulin degludec, Tresiba
- Where
- China
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Type 1 Diabetes, Type 1 Diabetes Mellitus
Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas
One of the main challenges in maintaining tight glucose control in a closed-loop system occurs at meal times. Amylin is a gluco-regulatory beta-cell hormone that is co-secreted with insulin in response to nutrient stimuli, and is…
- Conditions
- Type 1 Diabetes, Type 1 Diabetes Mellitus, Hyperglycemia, Postprandial
- Trial name
- NCT04163874
- Testing
- Fiasp, Pramlintide Acetate, Artificial Pancreas
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- McGill University
Healthy Volunteers, Diabetes Mellitus, Type 2
A Study to Look at How Safe NNC0472-0147 is in Healthy People and in People With Type 2 Diabetes
This study is investigating the safety and tolerability of the new medicine NNC0472-0147, its concentrations in the blood and its effect on blood sugar for the treatment of diabetes.
- Trial name
- NCT04262661
- Testing
- NNC0472-0147, insulin glargine
- Where
- 2 sites in Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes, Obesity
Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity
Type 2 diabetes (T2D) is a progressive chronic condition associated with a high morbi-mortality that has a considerable impact on healthcare resources.
- Trial name
- NCT05535322
- Testing
- GLP-1RA, SGLT2i, Insulin
- Where
- Spain
- Volunteers
- 26,944 people
- Sponsor
- Ana Palanca
Type 2 Diabetes Mellitus
A Pooled Analysis of the Safety and Efficacy of MK-0431A and MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) (MK-0431A-170/MK-0431A-289)
The purpose of this study is to assess the effect of the addition of sitagliptin (administered as MK-0431A or MK-0431A XR) relative to the addition of placebo on glycated hemoglobin (A1C), and the safety and tolerability of the…
- Trial name
- NCT01760447
- Testing
- Sitagliptin plus metformin, Metformin, Sitagliptin plus metformin XR
- Volunteers
- 223 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers
This is a phase 1 study to demonstrate pharmacokinetic and pharmacodynamic similarity between HEC-Glargine and US-Lantus® using the euglycemic clamp technique in healthy male adult volunteers.
- Trial name
- NCT05248841
- Testing
- HEC-Glargine, US-Lantus
- Where
- South Africa
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Lannett Company, Inc.
Diabetes Mellitus, Type 1
AT247, NovoLog® and Fiasp® Administered Via Continuous Subcutaneous Infusion in Glucose Clamp Study
Phase 1 randomized, double-blind, three period, crossover study comparing the pharmacodynamic, pharmacokinetic, safety and tolerability profiles for Arecor ultra-rapid insulin aspart (AT247), NovoLog® and Fiasp® in participants…
- Trial name
- NCT05184868
- Testing
- AT247, NovoLog, Fiasp
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arecor Limited
Diabetes Mellitus, Type 2
A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes
This study looks at the safety and tolerability of the new medicine NNC0268-0965 (referred to as insulin 965), its concentration in the blood and its effect on the blood sugar for the treatment of diabetes.
- Trial name
- NCT04136067
- Testing
- NNC0268-0965, insulin glargine
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
Retrospective multicenter study analyzing data gathered during the FUTURE study (S59342) to assess the effect of using Insulin Glargine 300 U/mL (Gla-300) on measures of diabetes control and quality of life.
- Trial name
- FUTURE-GLARE (NCT05109520)
- Testing
- Insulin Glargine 300 UNT/ML [Toujeo]
- Where
- 3 sites in Belgium
- Volunteers
- 867 people
- Sponsor
- prof dr Pieter Gillard
Diabetes Mellitus, Type 2
A Study to Evaluate Eli Lilly's Insulin Dosing Algorithm to Control Glycemia in Insulin-treated Adults With Type 2 Diabetes
The objective of this study is to generate preliminary data in an inpatient setting to help optimize an insulin dosing logic (that decides how much to deliver insulin) for Eli Lilly's system.
- Trial name
- NCT05514080
- Testing
- Insulin closed-loop
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- McGill University
Diabetes Mellitus, Type 1
Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart
The main objective of the study is to determine whether automated closed-loop using faster-acting insulin aspart will improve glucose control and reduce the burden of hypoglycaemia over a 23-hour period compared to insulin aspart…
- Trial name
- AP-MFT-01 (NCT03579615)
- Testing
- FIASP + closed loop device, Insulin aspart (standard of care insulin) + closed loop device
- Where
- United Kingdom
- Volunteers
- 18 people
- Sponsor
- Manchester University NHS Foundation Trust